S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

$5.01
+0.01 (+0.20%)
(As of 05:21 PM ET)
Today's Range
$4.97
$5.04
50-Day Range
$4.93
$8.32
52-Week Range
$4.85
$12.43
Volume
1.37 million shs
Average Volume
2.41 million shs
Market Capitalization
$724.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Aurinia Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
99.6% Upside
$10.00 Price Target
Short Interest
Healthy
8.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.06) to $0.55 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.59 out of 5 stars

Medical Sector

716th out of 938 stocks

Pharmaceutical Preparations Industry

322nd out of 425 stocks

AUPH stock logo

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

AUPH Stock Price History

AUPH Stock News Headlines

11 Oversold Biotech Stocks To Buy Right Now
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
AUPH Mar 2024 3.000 call
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Aurinia Pharmaceuticals Inc (AUPH)
AUPH Oct 2024 8.000 call
AUPH Jan 2025 15.000 call
AUPH Oct 2024 6.000 put
Earnings Outlook For Aurinia Pharmaceuticals
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$13.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+98.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-78,020,000.00
Pretax Margin
-44.14%

Debt

Sales & Book Value

Annual Sales
$175.51 million
Book Value
$2.63 per share

Miscellaneous

Free Float
138,399,000
Market Cap
$727.44 million
Optionable
Optionable
Beta
1.37
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives


AUPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price target for 2024?

4 Wall Street research analysts have issued 1-year price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $8.00 to $13.00. On average, they predict the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 99.6% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2024?

Aurinia Pharmaceuticals' stock was trading at $8.99 at the beginning of the year. Since then, AUPH stock has decreased by 44.3% and is now trading at $5.01.
View the best growth stocks for 2024 here
.

Are investors shorting Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 10,650,000 shares, a drop of 12.0% from the February 29th total of 12,100,000 shares. Based on an average daily trading volume, of 2,360,000 shares, the days-to-cover ratio is currently 4.5 days. Approximately 8.3% of the company's shares are sold short.
View Aurinia Pharmaceuticals' Short Interest
.

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUPH earnings forecast
.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.03. The biotechnology company earned $45.10 million during the quarter, compared to analyst estimates of $45 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative trailing twelve-month return on equity of 20.10%. Aurinia Pharmaceuticals's revenue was up 58.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.18) earnings per share.

What ETFs hold Aurinia Pharmaceuticals' stock?

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings?

Aurinia Pharmaceuticals issued an update on its fourth quarter 2023 earnings guidance on Friday, January, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $45.0 million-$45.0 million, compared to the consensus revenue estimate of $44.2 million.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (6.64%), Goldman Sachs Group Inc. (1.43%), Goldman Sachs Group Inc. (1.42%), Vanguard Group Inc. (1.04%), Vanguard Group Inc. (1.05%) and Northern Trust Corp (0.74%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends
.

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUPH) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners